Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. Its platform allows for the creation of multiple PDTs that are designed to treat patients with CBT, delivered digitally via an app, to address the underlying causes of CMDx. Its lead PDT product candidate, AspyreRx, is a digital behavioral therapeutic delivering CBT for the treatment of a cardiometabolic disease. AspyreRx is a prescription-only digital treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D. Its pipeline also includes programs for the treatment of hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH) and chronic kidney disease.
Follow-Up Questions
¿Quién es el CEO de Better Therapeutics Inc?
Mr. Craig Jalbert es el President de Better Therapeutics Inc, se unió a la empresa desde 2024.
¿Qué tal es el rendimiento del precio de la acción BTTX?
El precio actual de BTTX es de $0.0002, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Better Therapeutics Inc?
Better Therapeutics Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Better Therapeutics Inc?
La capitalización bursátil actual de Better Therapeutics Inc es $9972
¿Es Better Therapeutics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 4 analistas han realizado calificaciones de análisis para Better Therapeutics Inc, incluyendo 2 fuerte compra, 5 compra, 1 mantener, 0 venta, y 2 fuerte venta
